Role of endothelial kinins in control of coronary nitric oxide production

Hypertension

Volumn 30, Issue 5, 1997, Pages 1105-1111

  Zhang, Xiaoping ^a   Scicli, Guillermo A ^b   Xu, Xiaobin ^a   Nasjletti, Alberto ^a   Hintze, Thomas H ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b HENRY FORD HOSPITAL   (United States)

Author keywords

Kallikrein kinin system; Kininogen; Nitric oxide synthase; Serine protease inhibitors

Indexed keywords

CAPTOPRIL; ENALAPRILAT; KININ; NITRIC OXIDE; RAMIPRILAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DOG; ENZYME ACTIVATION; ENZYME INACTIVATION; ENZYME INHIBITION; KALLIKREIN KININ SYSTEM; MEDIATOR RELEASE; MICROVASCULATURE; NONHUMAN; PRIORITY JOURNAL; VASCULAR SMOOTH MUSCLE;

EID: 0030692140     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.30.5.1105     Document Type: Article

References (38)

1. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991;43: 109-141.
2. Bhoola KD, Figueroa CD, Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev. 1992;44:1-80.
3. Regoli D, Barabe J. Pharmacology of bradykinin and related kinins. Pharmacol Rev. 1980;32:1-46.
4. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of the arterial smooth muscle by acetylcholine. Nature. 1980;286:373-376.
5. Furchgott RF. The role of endothelium in the response of vascular smooth muscle to drugs. Annu Rev Pharmacol Toxicol. 1984;24: 175-197.
6. Palmer RMJ, Ferrige AG, Moncada S, Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987;327:524-526.
7. Moroi M, Akatsuka N, Fukazawa M, Hara K, Ishikawa M, Aikawa J, Namiki A, Yamaguchi T, Endothelium-dependent relaxation by angiotensin-converting enzyme inhibitors in canine femoral arteries. Am J Physiol. 1994;266:H583-H589.
8. Linz W, Wiemer G, Gohlke P, Linger T, Scholkens BA. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev. 1995;47:25-49.
9. 2 kinin receptors in the bovine isolated coronary artery. Br J Pharmacol. 1995;116: 2473-2481.
10. Vanhoutte PM, Boulanger CM, Mombouli JV. Endothelium-derived relaxation factors and converting enzyme inhibition. Am J Cardiol. 1995;76:3E-12E.
11. Piana RN, Wang SY, Friedman M, Selke FW. Angiotensin-converting enzyme inhibition preserves Endothelium-dependent coronary microvascular responses during short-term ischemia-reperfusion. Circulation. 1996;93:544-551.
12. Mombouli JV, Vanhoutte PM. Kinins and endothelial control of vascular smooth muscle. Annu Rev Pharmacol Toxicol. 1995;35: 679-705.
13. Fukuto JM, Chaudhuri G. Inhibition of constitutive and inducible nitric oxide synthase: potential selective inhibition. Annu Rev Pharmacol Toxicol. 1995;35:165-194.
14. Nolly HL, Lama MC, Carretero OA, Scicli AG. The kallikrein-kinin system in blood vessels. Agents Actions Suppl. 1992; 38(suppl III):1-9.
15. Nolly HL, Carretero OA, Scicli AG. Kallikrein release by vascular tissue. Am J Physiol. 1993;265:H1209-H1214.
16. Savoy-Moore, RT, Khullar M, Swartz K, Scicli AG, Carretaro OA. Characterization of monoclonal antibodies against rat glandular kallikrein. J Immunol Methods. 1986;88:512-545.
17. Groves P, Kurz S, Just H, Drexler H. Role of endogenous bradykinin in human coronary vasomotor control. Circulation. 1995; 92:3424-3430.
18. Graf BK, Grafe M, Auch-Schwelk W, Baumgarten CR, Scheffer H, Hildebrandt A, Fleck E. Tissue kallikrein activity and kinin release in human endothelial cells. Eur J Clin Chem Clin Biochem. 1994; 32:495-500.
19. Seyedi N, Xu X, Nasjletti A, Hintze TH. Coronary kinin generation mediates nitric oxide release after angiotensin receptor stimulation. Hypertension. 1995;26:164-170.
20. Zhang XP, Xie YW, Nasjletti A, Xu X, Wolin MS, Hintze TH. Ace inhibitors stimulate nitric oxide production to modulate myocardial oxygen consumption. Circulation. 1997;95:176-182.
21. Kichuk MR, Seyedi N, Zhang X, Marboe CC, Michler RE, Addonizio LJ, Kaley G, Nasjletti A, Hintze TH. Regulation of nitric oxide production in human coronary microvessels and the contribution of local kinin formation. Circulation. 1996;94:44-51.
22. Gerritsen ME, Printz MP. Sites of prostaglandin synthesis in the bovine heart and isolated bovine coronary microvessels. Circ Res. 1981;49:1152-1163.
23. Margolius HS. Kallikreins and kinin molecular characteristics and cellular and tissue responses. Diabetes. 1996;45(suppl 1):S14-S19.
24. Hecher M, Porsti I, Bara AT, Busse R. Potentiation by ACE inhibitors of the dilator response to bradykinin in the coronary microcirculation: interaction at the receptor level. Br J Pharmacol. 1994;111:238-244.
25. Wiemer G, Scholkens BA, Becker RHA, Busse R. Ramiprilat enhances endothelial autacoid formation by inhibiting breakdown of endothelium-derived bradykinin. Hypertension. 1991;18:558-563.
26. Wiemer G, Scholkens BA, Linz W. Endothelial protection by converting enzyme inhibitors. Cardiovasc Res. 1994;28:166-172.
27. Grafe M, Bossaller C, Graf K, Auch-schwelk W, Baumgarten CR, Hildebrandt A, Fleck E. Effect of angiotensin-converting-enzyme inhibition on bradykinin metabolism by vascular endothelial cells. Am J Physiol. 1993;264:H1493-H1497.
28. Hasan AAK, Zhang J, Samuel M, Schmaier AH. Conformational changes in low molecular weight kininogen alters its ability to bind to endothelial cells. Thromb Haemost. 1995;74:1088-1095.
29. Seyedi N, Nasjletti A, Xu X, Hintze TH. A23187 induced calcium influx is a co-factor for local kinin formation and not NO synthase in coronary microvessels. Circulation. 1994;90(suppl I):I-105. Abstract.
30. 1 receptors: a review. Immunopharmacology, 1995;30:1-26.
31. Erdos EG. Some old and some new ideas on kinin metabolism. J Cardiovasc Pharmacol. 1990;15(suppl 6):S20-S24.
32. Busse R, Fleming I. Molecular responses of endothelial tissue to kinins. Diabetes. 1996;45(suppl 1):S8-S12.
33. Schmaier AH, Kuo A, Lundberg D, Murray S, Cines DB. The expression of high molecular weight kininogen on human umbilical vein endothelial cells. J Biol Chem. 1988;263:16327-16333.
34. Iwaarden FV, Groot PG, Sixma JJ, Berrettini M, Bouma BN. High-molecular weight kininogen is present in cultured human endothelial cells: localization, isolation, and characterization. Blood. 1988;71:1268-1276.
35. Zini JM, Schmaier AH, Cines DB. Bradykinin regulates the expression of kininogen binding sites on endothelial cells. Blood. 1993;81:2936-2946.
36. Herwald H, Hasan AAK, Godovac-Zimmermann J. Identification of an endothelial cell binding site on kininogen domain D3. J Biol Chem. 1995;270:14634-14642.
37. Hasant AAK, Cines DB, Zhang J, Schmaier AH. The carboxyl terminus of bradykinin and amino terminus of the light chain of kininogens comprise an endothelial cell binding domain. J Biol Chem. 1994;269:31822-31830.
38. Hasan AAK, Cines DB, Ngaiza JR, Jaffe EA, Schmaier AH. High-molecular-weight kininogen is exclusively membrane bound on endothelial cells to influence activation of vascular endothelium. Blood. 1995;85:3134-3143.